Dr. Kiran Naqvi
Claim this profileM D Anderson Cancer Center
Affiliated Hospitals
M D Anderson Cancer Center
MD Anderson Regional Care Center-Bay Area
Clinical Trials Kiran Naqvi is currently running
SNDX-5613 + Chemotherapy
for Acute Myeloid Leukemia
This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemia that has changes in the NPM1 gene or MLL/KMT2A gene. SNDX-5613 blocks signals passed from one molecule to another inside cancer cells that are needed for cancer cell survival. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding SNDX-5613 to the standard chemotherapy treatment may be able to shrink or stabilize the cancer for longer than the standard chemotherapy treatment alone.
Recruiting
1 award
Phase 1
Iadademstat + Venetoclax + Azacitidine
for Acute Myeloid Leukemia
This phase I trial tests safety, side effects and best dose of iadademstat with azacitidine and venetoclax for the treatment of patients with acute myeloid leukemia (AML) who have not received treatment (treatment naive). Chemotherapy drugs, such as iadademstat and azacitidine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving iadademstat with azacitidine and venetoclax may be safe and tolerable in treating patients with treatment naive AML.
Recruiting
1 award
Phase 1
5 criteria
More about Kiran Naqvi
Clinical Trial Related
1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Kiran Naqvi has experience with
- Venetoclax
- Arsenic Trioxide
- Gemtuzumab Ozogamicin
- Tretinoin
- Cytarabine
- Milademetan Tosylate
Breakdown of trials Kiran Naqvi has run
Acute Myeloid Leukemia
Acute Myelogenous Leukemia
Acute Promyelocytic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kiran Naqvi specialize in?
Kiran Naqvi focuses on Acute Myeloid Leukemia and Acute Myelogenous Leukemia. In particular, much of their work with Acute Myeloid Leukemia has involved treating patients, or patients who are undergoing treatment.
Is Kiran Naqvi currently recruiting for clinical trials?
Yes, Kiran Naqvi is currently recruiting for 4 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Kiran Naqvi has studied deeply?
Yes, Kiran Naqvi has studied treatments such as Venetoclax, Arsenic Trioxide, Gemtuzumab Ozogamicin.
What is the best way to schedule an appointment with Kiran Naqvi?
Apply for one of the trials that Kiran Naqvi is conducting.
What is the office address of Kiran Naqvi?
The office of Kiran Naqvi is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.